Practicing in an Era of Chemotherapy-Free Regimens for Relapsed/Refractory Chronic Lymphocytic Leukemia
Time to Complete
June 24, 2019
June 24, 2020
1.00 / AMA PRA Category 1 CreditTM
Provided by The University of Texas MD Anderson Cancer Center
Supported by an educational grant from AbbVie Inc.
Produced by Haymarket Medical Education
While many patients with chronic lymphocytic leukemia (CLL) respond to first-line chemotherapeutic regimens, up to 60% of patients fail to achieve complete remission and a majority of patients relapse within 5 years. However, a treatment paradigm shift has taken place in the last few years in the relapsed/refractory (R/R) setting with the availability of several oral medications that target specific dysregulated pathways implicated in the pathogenesis of CLL. With these rapid changes, it is difficult for clinicians to keep abreast of the most current efficacy and safety data of the spectrum of targeted agents—eg, BCL2, CD20, PI3Kδ, PI3KδƳ, and BTK inhibitors—that now inform current National Comprehensive Cancer Network (NCCN) treatment guidelines. The education is designed to provide oncologists who treat patients with R/R CLL with up-to-date knowledge of current therapeutic options so that they, in turn, can effectively convey to patients the benefits, risks, complications, and any additional information that is important to the preferences of these patients as they take a more active role in the selection of their therapeutic regimen.
Hematologist-oncologists, hematologists, medical oncologists, nurse practitioners (NPs), physician assistants (PAs), and other healthcare professionals involved in the care and treatment of patients with R/R CLL
At the conclusion of this activity, participants should be better able to:
Assess key prognostic, predictive, and clinical factors that drive consideration of second-line therapy, treatment sequencing, and durable remission for patients with chronic lymphocytic leukemia (CLL)
Summarize the most up-to-date guideline-recommended treatments for patients with R/R CLL
Describe the key clinical trial results and subset analyses demonstrating the efficacy and safety of targeted regimens in the R/R CLL setting, including BCL2, CD20, PI3Kδ, PI3KδƳ,and BTK inhibitors
Analyze the clinical trial end points of overall survival, response rate, and clearance of minimal residual disease of venetoclax-rituxumab combination therapy compared with bendamustine-rituxumab
Employ effective communication strategies using core shared decision-making principles with patients and their caregivers, incorporating patient values, goals, informed preferences, and concerns into the final treatment plan
Conflict Of Interest Disclosure Policy
The Accreditation Council for Continuing Medical Education (ACCME) has announced standards and guidelines to ensure that individuals participating in CME activities are aware of program chair's/chairs', planning committee members’, faculty’s/teachers’/authors’, and CME activity reviewers’ relationships with commercial interests that could potentially affect the information presented. The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest.
The University of Texas MD Anderson Cancer Center has, through a formal review process, resolved all potential conflicts of interest prior to this activity. For information on this process, please contact CME/Conference Management at 713-792-5357.
The following faculty have financial interests, arrangements, or affiliations with the manufacturer of any products or devices to be discussed or who may financially support this CME activity, as indicated below. An asterisk (*) indicates that the faculty’s presentation will include discussion of investigational or off-label uses of products.
Nitin Jain, MD – Chair Associate Professor of Medicine Department of Leukemia MD Anderson Cancer Center Houston, TX
Dr. Jain* discloses the following: Grant research support: ADC Therapeutics, AstraZeneca, Bristol-Myers Squibb, Celgene, Cellectis, Genentech, Incyte Corporation, Laboratoires Servier, Pfizer Inc., Pharmacyclics, Precision Biosciences, Seattle Genetics, and Verastem Oncology Honoraria: AbbVie Inc., ADC Therapeutics, AstraZeneca, Genentech, Janssen Pharmaceuticals, Inc., Laboratoires Servier, Pfizer Inc., Pharmacyclics, Precision Biosciences, and Verastem Oncology Membership on advisory committees: AbbVie Inc., ADC Therapeutics, AstraZeneca, Celgene, Genentech, Janssen Pharmaceuticals, Inc., Laboratoires Servier, Pfizer Inc., Pharmacyclics, Precision Biosciences, and Verastem Oncology
Danielle M. Brander, MD Assistant Professor of Medicine Division of Hematologic Malignancies and Cellular Therapy Duke University Medical Center Durham, NC
Dr. Brander* discloses the following: Grant research support: AbbVie Inc., Acerta Pharma LLC, BeiGene, DTRM Biopharma Co. Ltd., Genentech, MEI Pharma, and TG Therapeutics, Inc. Paid consultant: AbbVie Inc., AstraZeneca, Novartis Pharmaceuticals Corporation, Pharmacylics, and Teva Pharmaceuticals USA, Inc. Membership on scientific advisory boards: AbbVie Inc., Genentech, Teva Pharmaceuticals USA, Inc., and TG Therapeutics, Inc. Membership on data safety monitoring board (DSMB): Novartis Pharmaceuticals Corporation
David A. Rizzieri, MD Professor of Medicine Chief, Section of Hematologic Malignancies Associate Director, Clinical Research Division of Hematologic Malignancies and Cellular Therapy Duke Cancer Institute Durham, NC
Dr. Rizzieri* discloses the following: Membership on advisory committees: AbbVie Inc., Arog Pharmaceuticals, Inc., Bayer, Celgene, Celltrion Inc., Gilead Sciences, Inc., Incyte Corporation, Jazz Pharmaceuticals, Kite Pharma, Mustang Bio, Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., Pharmacyclics, Sanofi, Seattle Genetics, Stemline Therapeutics Inc., and Teva Pharmaceutical Industries. Speakers’ bureaus: Celgene, Gilead Sciences, Inc., Incyte Corporation, Seattle Genetics, and Stemline Therapeutics Inc.
The following Faculty/Program Planning Committee Members and CME Activity Reviewers/Approvers HAVE INDICATED THEY HAVE NO FINANCIAL INTERESTS, arrangements or affiliations with the manufacturer of any product or devices to be discussed, or who may financial support this CME activity. An asterisk (*) indicates that the faculty’s presentation will include discussion of investigational or off-label uses of a product.
Planning Committee Members Danielle M. Brander, MD: See disclosure above Angie Castillo Tamara C. Greiner, MA, CHCP Nitin Jain, MD: See disclosure above Lori Marrese David A. Rizzieri, MD: See disclosure above Priya Wanchoo, MD, CHCP Nick Zittell, CHCP
CME Activity Reviewers/Approvers Jose Banchs, MD Diane C. Bodurka, MD Pei Lin, MD Issa Khouri, MD Paid consultant: AbbVie Inc. and Takeda Pharmaceutical Company Ltd.
AMA PRA Category 1 Credit(s)TM
The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Texas MD Anderson Cancer Center designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Additional Credit Information
Physician Assistant Continuing Education AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.00 Category 1 Credit for completing this activity.
Nurse Practitioner Continuing Education The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Disclosure of Unlabeled Use
This CME activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. Haymarket Medical Education and MD Anderson require the speaker to disclose that a product is not labeled for the use under discussion.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This activity will take approximately 60 minutes to complete. To receive credit, participants are required to view the online activity and complete the post-test and evaluation. To receive credit, a score of 75% or higher must be achieved on the post-test. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
If you have any questions relating to the accreditation of this activity, please contact Tamara C. Greiner at firstname.lastname@example.org.